Mp17-19 gene mutations among prostate cancer patients with a smoking history

You have accessJournal of UrologyCME1 Apr 2023MP17-19 GENE MUTATIONS AMONG PROSTATE CANCER PATIENTS WITH A SMOKING HISTORY Ahmed El-shafie, Allison H. Feibus, Mohammed Al-Toubat, Navid Lelani, SeyedBehzad Jazayeri, Kashyap Koul, Robert A. Marino, Mark Bandyk, Joseph Costa, and K. C. Balaji Ahmed El-shafieAhmed El-shafie More articles by this author , Allison H. FeibusAllison H. Feibus More articles by this author , Mohammed Al-ToubatMohammed Al-Toubat More articles by this author , Navid LelaniNavid Lelani More articles by this author , SeyedBehzad JazayeriSeyedBehzad Jazayeri More articles by this author , Kashyap KoulKashyap Koul More articles by this author , Robert A. MarinoRobert A. Marino More articles by this author , Mark BandykMark Bandyk More articles by this author , Joseph CostaJoseph Costa More articles by this author , and K. C. BalajiK. C. Balaji More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003237.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Tobacco smoking has been established as a risk factor for a majority of cancers, representing one of the most important modifiable risk factors. However, the association between smoking and prostate cancer (PCa) remains unclear. We compared gene mutations using a next generation sequencing (NGS) database of smokers and non-smokers with PCa. METHODS: Data is derived from the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) registry. We included 1832 men with PCa in our study cohort, categorized as either smokers or non/never smokers. We compared the frequency of mutations (point mutations, copy number variations and structural variants) of 47 genes between the 2 groups. We also studied the association of the gene mutations with overall survival. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with mortality. RESULTS: Within the study cohort, 1007 (55%) patients were non-smokers and the remaining 825 (45%) were smokers. Patients with a smoking history had a higher percentage of somatic mutations in PREX2 (p=0.018), PTEN (p=0.02), AGO2 (p=0.03), and KMT2C (p=0.04) compared to non-smokers. In contrast, non-smokers had a higher percentage of somatic mutations in APC (p=0.02) and KMT2A (p=0.04) compared to smokers. The mortality rate was significantly higher among the smoker population (p=0.006). The presence of metastatic disease at the time of diagnosis (OR 2.26, p<0.001), smoking history (OR 1.32, p=0.02), and PTEN somatic gene mutation (OR 1.89, p<0.001) were independent predictors of mortality among patients diagnosed with PCa (Table 1). CONCLUSIONS: PCa patients with a tobacco smoking history had significantly higher somatic mutations of PREX2, KMT2C, AGO2, and PTEN genes. Moreover, PTEN somatic gene mutation is linked to mortality among patients with PCa (Figure 1). Source of Funding: none © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e220 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ahmed El-shafie More articles by this author Allison H. Feibus More articles by this author Mohammed Al-Toubat More articles by this author Navid Lelani More articles by this author SeyedBehzad Jazayeri More articles by this author Kashyap Koul More articles by this author Robert A. Marino More articles by this author Mark Bandyk More articles by this author Joseph Costa More articles by this author K. C. Balaji More articles by this author Expand All Advertisement PDF downloadLoading ...